Resumen

PORTELLES CRUZ, Alexander et al. Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. CCM [online]. 2013, vol.17, n.4, pp.333-442. ISSN 1560-4381.

Introduction: breast cancer is the most common malignant tumor in women at this moment.  Chemotherapy is one of the main therapeutic tools against this pathology. Objective: characterize the behavior of patients with local advanced breast cancer who recieved neoadyuvant chemotherapy at Holguín Oncological Center from January 2010 to December 2011 Methods: a prospective and descriptive study was carried out. All patients with breast cancer were the universe and the sample comprised 87 patients who completed all the treatment. Results: women were the predominant gender (96.56%) as well as the age group between 40-49 years (35.63%). Doxorubicin with Cyclophosphamide treatment prevailed (44.83%) and 37.93% of these patients received four cycles of it. The toxicity by chemotherapy did not interfere in this therapy and nauseas with or without vomiting was the most frequent adverse reaction (90.80%). Most patients assimilated the treatment partially 55.17% of them. Thus, with this treatment there was a partial recovery in the majority of patients and the toxicity did not delay the therapy. Conclusions: locally advanced breast cancer could be found commonly in 40-49 years old women. Chemotherapy schedule more frequently used was the junctions of doxorubicin and cyclophosphamide, reaching a partial response in the majority number of patients and the toxicity never delay the therapy.

Palabras clave : locally advanced breast cancer; neoadyuvant chemotherapy; adriamycin with cyclophosphamide.

        · resumen en Español     · texto en Español     · Español ( pdf )